Athersys Inc. won Food & Drug Administration approval to begin a Phase II trial of its MultiStem stem cell treatmen for inflammatory bowel disease and posts wider third-quarter losses.
Athersys Inc. (NSDQ:ATHX) received the regulatory thumbs-up to begin a Phase II clinical trial of its MultiStem stem cell treatment for inflammatory bowel disease.
Get the complete picture with a MassDevice Plus membership. Registered users can login here.